Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?

Cancer Epidemiology

Volumn 34, Issue 5, 2010, Pages 580-586

  Gaudet, Mia M ^a   Falk, Roni T ^b   Gierach, Gretchen L ^b   Lacey, James V ^b   Graubard, Barry I ^b   Dorgan, Joanne F ^c   Brinton, Louise A ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Adipokines; Biomarkers; Breast cancer; Epidemiology; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ESTRADIOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; SEX HORMONE BINDING GLOBULIN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADIPOKINES; ADIPONECTIN; AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPRODUCIBILITY OF RESULTS; RESISTIN; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; UNITED STATES;

EID: 77957230259     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.05.014     Document Type: Article

References (26)

1. Cleary M.P., Grossmann M.E. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 2009, 150(6):2537-2542.
2. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92(3):347-355.
3. Schaffler A., Scholmerich J., Buechler C. Mechanisms of disease: adipokines and breast cancer-endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 2007, 3(4):345-354.
4. Tworoger S.S., Eliassen A.H., Kelesidis T., Colditz G.A., Willett W.C., Mantzoros C.S., et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007, 92(4):1510-1516.
5. Cust A.E., Stocks T., Lukanova A., Lundin E., Hallmans G., Kaaks R., et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009, 113(3):567-576.
6. Dorgan J.F., Longcope C., Stephenson H.E., Falk R.T., Miller R., Franz C., et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996, 5(7):533-539.
7. Dorgan J.F., Stanczyk F.Z., Longcope C., Stephenson H.E., Chang L., Miller R., et al. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1997, 6(3):177-181.
8. Mantzoros C., Petridou E., Dessypris N., Chavelas C., Dalamaga M., Alexe D.M., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89(3):1102-1107.
9. Chen D.C., Chung Y.F., Yeh Y.T., Chaung H.C., Kuo F.C., Fu O.Y., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006, 237(1):109-114.
10. Miyoshi Y., Funahashi T., Kihara S., Taguchi T., Tamaki Y., Matsuzawa Y., et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9(15):5699-5704.
11. Dieudonne M.N., Bussiere M., Dos Santos E., Leneveu M.C., Giudicelli Y., Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006, 345(1):271-279.
12. Takahata C., Miyoshi Y., Irahara N., Taguchi T., Tamaki Y., Noguchi S. Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells. Cancer Lett 2007, 250(2):229-236.
13. Kang J.H., Lee Y.Y., Yu B.Y., Yang B.S., Cho K.H., Yoon D.K., et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 2005, 28(11):1263-1269.
14. Castello R., Landete J.M., Espana F., Vazquez C., Fuster C., Almenar S.M., et al. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res 2007.
15. Mertens I., Van der Planken M., Corthouts B., Wauters M., Peiffer F., De Leeuw I., et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001, 33(10):602-607.
16. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94(2):116-128.
17. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145(5):2273-2282.
18. Bastelica D., Morange P., Berthet B., Borghi H., Lacroix O., Grino M., et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002, 22(1):173-178.
19. Lindeman J.H., Pijl H., Toet K., Eilers P.H., van Ramshorst B., Buijs M.M., et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond) 2007, 31(11):1671-1679.
20. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci 2004, 61(19/20):2485-2496.
21. Fain J.N., Cheema P.S., Bahouth S.W., Lloyd Hiler M Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003, 300(3):674-678.
22. Aquilante C.L., Kosmiski L.A., Knutsen S.D., Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008, 57(4):494-501.
23. Norata G.D., Ongari M., Garlaschelli K., Raselli S., Grigore L., Catapano A.L. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007, 156(2):279-284.
24. Hou W.K., Xu Y.X., Yu T., Zhang L., Zhang W.W., Fu C.L., et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007, 120(18):1592-1596.
25. Kang J.H., Yu B.Y., Youn D.S. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007, 22(1):117-121.
26. Hill M.J., Kumar S., McTernan P.G. Adipokines and the clinical laboratory: what to measure, when and how?. J Clin Pathol 2009, 62(3):206-211.